HANUMAN, I suspect CYGX's patent application . . .
of May 1, 2003 -- http://tinyurl.com/37u4s -- thoroughly protects the company's proprietary plasmid expression vector, but your question can really only be answered by the company. Malcolm Skolnick would be the best person to ask, but you could also try the company's IR guy, Juan Ferreira.
It'd be a great question to be raised at the SHM (that's a hint for anyone going to the meeting!).